|
WHAT:
|
Pfizer Oncology will host a journalist briefing at the American |
|
|
Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, |
|
|
June 1, 2008, highlighting key data presentations from a variety |
|
|
of compounds in several difficult-to-treat tumor types, |
|
|
including renal cell carcinoma and non-small cell lung cancer. |
|
|
Leading oncology physicians and researchers will present study |
|
|
results and offer their professional perspective. |
|
|
|
WHO:
|
Robert Figlin, M.D., F.A.C.P., City of Hope
|
|
|
Abstract #5024: "Overall survival with sunitinib versus |
|
|
interferon (IFN)-alfa as first-line treatment of metastatic |
|
|
renal cell carcinoma (mRCC)" |
|
|
|
|
Antonio Gualberto, M.D., Ph.D., Pfizer Global Research and
|
|
|
Development
|
|
|
Abstract #10501: "Safety, pharmacokinetics and preliminary |
|
|
activity of the anti-IGF-1R antibody CP-751,871 in |
|
|
sarcoma patients" |
|
|
|
|
Daniel Karp, M.D., M.D. Anderson Cancer Center
|
|
|
Abstract #8000: "Characterization of NSCLC patients responding |
|
|
to anti-IGF-1R therapy" |
|
|
|
|
Pasi A. Janne, M.D., Ph.D., Dana-Farber Cancer Institute
|
|
|
Abstract #8027, Poster #8: "Preliminary activity and safety |
|
|
results from a phase I clinical trial of PF-00299804, an |
|
|
irreversible pan-HER inhibitor, in patients (pts) with NSCLC" |
|
|
|
|
John H. Sampson, M.D., Ph.D., Duke University Medical Center
|
|
|
Abstract #2061: "Effect of EGFRvIII-targeted vaccine (CDX-110) |
|
|
on immune response and TTP when given with simultaneous standard |
|
|
and continuous temozolomide in patients with GBM" |
|
|
|
WHEN:
|
Sunday, June 1, 2008 at 6:00 PM (CT)
|
|
|
|
WHERE:
|
Westin River North - Grand Ballroom A&B |
|
|
320 N. Dearborn Avenue |
|
|
Chicago, IL 60610 |
|
|
(312) 744-1900
|